LYEL

Lyell Immunopharma, Inc.
CAPPED RATING

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma, Inc. (LYEL) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F). The rating has held at D+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.6 / 5.0
D+
Value
F
Factor Score 0.0 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.6
EV / EBITDA -1.3
Rev Growth YoY -80.0%
Gross Margin N/M
Price Return 3M 12.1%
Price Return 12M -9.3%
Catalyst Signal 0.00
Market Cap $384.5M
TTM Revenue $15.0K
Price / Sales 25.6K
ROE -97.8%

Historical Factor Score Progression

Held D+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 F (0.0) D- (0.9) C (2.4) C- (2.1) C+ (2.6) D+ (1.6)
2026-11-06 F (0.0) D (1.3) C (2.4) C- (1.9) C+ (2.7) D+ (1.7)
2026-10-30 F (0.0) D (1.3) C (2.4) D+ (1.7) C+ (2.7) D+ (1.6)
2026-10-23 F (0.0) D (1.3) C (2.4) D (1.4) C+ (2.6) D+ (1.6)
2026-10-16 F (0.0) D (1.3) C (2.4) D (1.3) C+ (2.6) D+ (1.5)
Page 1 of 8
…